Home

Carrier Test Page

Genetics Alert
Save your life & Next Generation.

Neuronal Ceroid Lipofuscinosis, CLN5-Related

  • What is Neuronal Ceroid Lipofuscinosis, CLN5-Related?

    Neuronal Ceroid-Lipofuscinosis (NCL) is an inherited disease that affects neural systems. Patients with this disorder may have gradual loss of previously acquired skills, intellectual disability, behavioral problems, vision impairment, seizure and early death. NCL patients have been characterized traditionally according to the age of onset and order of appearance of clinical features into infantile, late-infantile, juvenile and adult types. Individuals with this condition often require the use of a wheelchair by late childhood and typically do not survive past their teens. Pathogenic variants in more than 10 genes can cause NCL and the most common genes include TPP1, PPT1, CLN3, CLN5, CLN6 and CLN8. Pathogenic variants in the CLN5 gene are the major cause of late infantile NCL.

  • How is Neuronal Ceroid Lipofuscinosis, CLN5-Related inherited?

    NCL caused by pathogenic variants in the CLN5 gene are inherited in an autosomal recessive manner. This type of inheritance requires the presence of two copies of a pathogenic variant in the gene for a person to have the genetic disease. Both parents must be carriers of a pathogenic variant in the gene in order to be at risk to have an affected child. The child must inherit a pathogenic variant from each carrier parent in order to be affected. There is a 1 in 4 chance that a baby will inherit two mutated copies of the gene and be affected when both parents are carriers.

  • What does it mean to be a carrier?

    There are generally no signs or symptoms associated with being a carrier for NCL. However, the risk to have a child affected with NCL is increased. Testing of reproductive partners is recommended for carriers of NCL.

  • How common is Neuronal Ceroid Lipofuscinosis, CLN5-Related?

    All types of NCL affect about 1 in 100,000 individuals worldwide. NCLs are more common in Finland, where approximately 1 in 12,500 individuals have the condition.

  • What is analysed?

    Full gene sequencing

AFFECTED SYSTEMS
Brain
Muscle
Eye
CARRIER RATES
Ethnicity Detection Rate Carrier Frequency
General Population > 94% 1 in 317